Mechanical circulatory support pathways that maximize post-heart transplant survival

Tara Karamlou, Jill Gelow, Brian S. Diggs, Frederick A. Tibayan, James M. Mudd, Steven W. Guyton, Matthew S. Slater, Howard K. Song

Research output: Contribution to journalArticle

Abstract

Background: Heart transplant (HTx) recipients reach transplantation through increasing numbers of support pathways, including transition from one pathway to another. Outcomes of patients successfully bridged with various support pathways are unknown. We sought to identify mechanical circulatory support pathways that maximize survival after HTx. Methods: A supplemented United Network Organ Sharing Dataset tracked status 1 HTx outcomes from 2000 to 2010. Recipients were grouped based on support pathway before HTx, including those transitioning from one pathway to another. Multivariable factors for time-related death were sought using Cox proportional hazard regression models. Results: We identified 13,250 status 1 HTx recipients. Initial support pathways were inotropes (n = 7,607), left ventricular assist device (LVAD [n = 4,034]), intraaortic balloon pump (n = 729), biventricular assist device (n = 521), extracorporeal membrane oxygenation (ECMO [n = 316]), and right ventricular assist device (n = 43). Multivariable analysis demonstrated that LVAD use conferred a survival advantage (hazard ratio [HR] 0.71; p <0.001), whereas all other support pathways, including inotropes (HR 1.1; p = 0.02), right ventricular assist device (HR 1.9; p = 0.01), and ECMO (HR 2.2; p <0.001) increased the risk of post-HTx death. Support pathway transition (both escalation and reduction) occurred in 2,175 patients. Patients who transitioned from either ECMO or biventricular assist device support at listing to LVAD-only support at HTx had improved post-HTx survival that was comparable to patients who had LVAD-only therapy throughout their course (p = 0.74). Conclusions: The LVAD supported HTx recipients have better posttransplant survival than patients after all other mechanical support pathways. Survival after HTx is optimized when ECMO or biventricular assist device support can be transitioned to LVAD-only support. Our findings should aid clinical decision making and inform organ allocation policy development intended to maximize societal benefits of HTx.

Original languageEnglish (US)
Pages (from-to)480-485
Number of pages6
JournalAnnals of Thoracic Surgery
Volume95
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Heart-Assist Devices
Transplants
Survival
Equipment and Supplies
Extracorporeal Membrane Oxygenation
Policy Making
Proportional Hazards Models
Transplantation
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Karamlou, T., Gelow, J., Diggs, B. S., Tibayan, F. A., Mudd, J. M., Guyton, S. W., ... Song, H. K. (2013). Mechanical circulatory support pathways that maximize post-heart transplant survival. Annals of Thoracic Surgery, 95(2), 480-485. https://doi.org/10.1016/j.athoracsur.2012.05.108

Mechanical circulatory support pathways that maximize post-heart transplant survival. / Karamlou, Tara; Gelow, Jill; Diggs, Brian S.; Tibayan, Frederick A.; Mudd, James M.; Guyton, Steven W.; Slater, Matthew S.; Song, Howard K.

In: Annals of Thoracic Surgery, Vol. 95, No. 2, 02.2013, p. 480-485.

Research output: Contribution to journalArticle

Karamlou, T, Gelow, J, Diggs, BS, Tibayan, FA, Mudd, JM, Guyton, SW, Slater, MS & Song, HK 2013, 'Mechanical circulatory support pathways that maximize post-heart transplant survival', Annals of Thoracic Surgery, vol. 95, no. 2, pp. 480-485. https://doi.org/10.1016/j.athoracsur.2012.05.108
Karamlou, Tara ; Gelow, Jill ; Diggs, Brian S. ; Tibayan, Frederick A. ; Mudd, James M. ; Guyton, Steven W. ; Slater, Matthew S. ; Song, Howard K. / Mechanical circulatory support pathways that maximize post-heart transplant survival. In: Annals of Thoracic Surgery. 2013 ; Vol. 95, No. 2. pp. 480-485.
@article{f4a0fea927e143ce82d7ad366ccb1729,
title = "Mechanical circulatory support pathways that maximize post-heart transplant survival",
abstract = "Background: Heart transplant (HTx) recipients reach transplantation through increasing numbers of support pathways, including transition from one pathway to another. Outcomes of patients successfully bridged with various support pathways are unknown. We sought to identify mechanical circulatory support pathways that maximize survival after HTx. Methods: A supplemented United Network Organ Sharing Dataset tracked status 1 HTx outcomes from 2000 to 2010. Recipients were grouped based on support pathway before HTx, including those transitioning from one pathway to another. Multivariable factors for time-related death were sought using Cox proportional hazard regression models. Results: We identified 13,250 status 1 HTx recipients. Initial support pathways were inotropes (n = 7,607), left ventricular assist device (LVAD [n = 4,034]), intraaortic balloon pump (n = 729), biventricular assist device (n = 521), extracorporeal membrane oxygenation (ECMO [n = 316]), and right ventricular assist device (n = 43). Multivariable analysis demonstrated that LVAD use conferred a survival advantage (hazard ratio [HR] 0.71; p <0.001), whereas all other support pathways, including inotropes (HR 1.1; p = 0.02), right ventricular assist device (HR 1.9; p = 0.01), and ECMO (HR 2.2; p <0.001) increased the risk of post-HTx death. Support pathway transition (both escalation and reduction) occurred in 2,175 patients. Patients who transitioned from either ECMO or biventricular assist device support at listing to LVAD-only support at HTx had improved post-HTx survival that was comparable to patients who had LVAD-only therapy throughout their course (p = 0.74). Conclusions: The LVAD supported HTx recipients have better posttransplant survival than patients after all other mechanical support pathways. Survival after HTx is optimized when ECMO or biventricular assist device support can be transitioned to LVAD-only support. Our findings should aid clinical decision making and inform organ allocation policy development intended to maximize societal benefits of HTx.",
author = "Tara Karamlou and Jill Gelow and Diggs, {Brian S.} and Tibayan, {Frederick A.} and Mudd, {James M.} and Guyton, {Steven W.} and Slater, {Matthew S.} and Song, {Howard K.}",
year = "2013",
month = "2",
doi = "10.1016/j.athoracsur.2012.05.108",
language = "English (US)",
volume = "95",
pages = "480--485",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Mechanical circulatory support pathways that maximize post-heart transplant survival

AU - Karamlou, Tara

AU - Gelow, Jill

AU - Diggs, Brian S.

AU - Tibayan, Frederick A.

AU - Mudd, James M.

AU - Guyton, Steven W.

AU - Slater, Matthew S.

AU - Song, Howard K.

PY - 2013/2

Y1 - 2013/2

N2 - Background: Heart transplant (HTx) recipients reach transplantation through increasing numbers of support pathways, including transition from one pathway to another. Outcomes of patients successfully bridged with various support pathways are unknown. We sought to identify mechanical circulatory support pathways that maximize survival after HTx. Methods: A supplemented United Network Organ Sharing Dataset tracked status 1 HTx outcomes from 2000 to 2010. Recipients were grouped based on support pathway before HTx, including those transitioning from one pathway to another. Multivariable factors for time-related death were sought using Cox proportional hazard regression models. Results: We identified 13,250 status 1 HTx recipients. Initial support pathways were inotropes (n = 7,607), left ventricular assist device (LVAD [n = 4,034]), intraaortic balloon pump (n = 729), biventricular assist device (n = 521), extracorporeal membrane oxygenation (ECMO [n = 316]), and right ventricular assist device (n = 43). Multivariable analysis demonstrated that LVAD use conferred a survival advantage (hazard ratio [HR] 0.71; p <0.001), whereas all other support pathways, including inotropes (HR 1.1; p = 0.02), right ventricular assist device (HR 1.9; p = 0.01), and ECMO (HR 2.2; p <0.001) increased the risk of post-HTx death. Support pathway transition (both escalation and reduction) occurred in 2,175 patients. Patients who transitioned from either ECMO or biventricular assist device support at listing to LVAD-only support at HTx had improved post-HTx survival that was comparable to patients who had LVAD-only therapy throughout their course (p = 0.74). Conclusions: The LVAD supported HTx recipients have better posttransplant survival than patients after all other mechanical support pathways. Survival after HTx is optimized when ECMO or biventricular assist device support can be transitioned to LVAD-only support. Our findings should aid clinical decision making and inform organ allocation policy development intended to maximize societal benefits of HTx.

AB - Background: Heart transplant (HTx) recipients reach transplantation through increasing numbers of support pathways, including transition from one pathway to another. Outcomes of patients successfully bridged with various support pathways are unknown. We sought to identify mechanical circulatory support pathways that maximize survival after HTx. Methods: A supplemented United Network Organ Sharing Dataset tracked status 1 HTx outcomes from 2000 to 2010. Recipients were grouped based on support pathway before HTx, including those transitioning from one pathway to another. Multivariable factors for time-related death were sought using Cox proportional hazard regression models. Results: We identified 13,250 status 1 HTx recipients. Initial support pathways were inotropes (n = 7,607), left ventricular assist device (LVAD [n = 4,034]), intraaortic balloon pump (n = 729), biventricular assist device (n = 521), extracorporeal membrane oxygenation (ECMO [n = 316]), and right ventricular assist device (n = 43). Multivariable analysis demonstrated that LVAD use conferred a survival advantage (hazard ratio [HR] 0.71; p <0.001), whereas all other support pathways, including inotropes (HR 1.1; p = 0.02), right ventricular assist device (HR 1.9; p = 0.01), and ECMO (HR 2.2; p <0.001) increased the risk of post-HTx death. Support pathway transition (both escalation and reduction) occurred in 2,175 patients. Patients who transitioned from either ECMO or biventricular assist device support at listing to LVAD-only support at HTx had improved post-HTx survival that was comparable to patients who had LVAD-only therapy throughout their course (p = 0.74). Conclusions: The LVAD supported HTx recipients have better posttransplant survival than patients after all other mechanical support pathways. Survival after HTx is optimized when ECMO or biventricular assist device support can be transitioned to LVAD-only support. Our findings should aid clinical decision making and inform organ allocation policy development intended to maximize societal benefits of HTx.

UR - http://www.scopus.com/inward/record.url?scp=84872788599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872788599&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2012.05.108

DO - 10.1016/j.athoracsur.2012.05.108

M3 - Article

VL - 95

SP - 480

EP - 485

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 2

ER -